UTZ vs MED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 18, 2026

UTZ

43.1
AI Score
VS
UTZ Wins

MED

40.1
AI Score

Investment Advisor Scores

UTZ

43score
Recommendation
HOLD

MED

40score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric UTZ MED Winner
Forward P/E 18.2815 12.4844 MED
PEG Ratio 0 0.972 Tie
Revenue Growth 1.4% -27.6% UTZ
Earnings Growth -47.8% -87.2% UTZ
Tradestie Score 43.1/100 40.1/100 UTZ
Profit Margin -2.0% -8.1% UTZ
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

UTZ 1M: -0.4% · 3M: +82.3% MED 1M: +26.5% · 3M: -5.4%

Current Technical Phase

UTZ

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (34.7% over 20 days), RSI 79

RSI (14): 79.3 · Price: $14.04

MED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 58.4 · Price: $11.95

Fundamentals Snapshot

Metric UTZ MED
Market Cap
Forward P/E 16.8 -42.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% -0.3%
Gross Margin 0.3% 0.7%
Operating Margin 0.0% -0.1%
EPS -0.33 -2.34
Dividend Yield 0.03%

Frequently Asked Questions

Based on our detailed analysis, UTZ is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.